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MaOBJECTIVES This study sought to assess the feasibility and safety of using a ﬁlter-based cerebral protection system
(CPS) during MitraClip implantation and to report on the histopathologic analysis of the captured debris.
BACKGROUND Stroke is one of the serious adverse events associated with MitraClip therapy.
METHODS Between July 2014 and March 2015, 14 surgical high-risk patients (age 75  7 years; 7 men; median logistic
EuroSCORE 21%) underwent MitraClip implantation employing cerebral protection with a dual embolic ﬁlter system. All
patients had severe mitral regurgitation of predominantly functional origin.
RESULTS All procedures were successfully completed for both CPS deployment/retrieval and MitraClip implantation.
A total of 28 ﬁlters (2 from each patient) were analyzed. Microscopically, debris was identiﬁed in all 14 patients. The most
common tissue types were acute thrombus and small fragments of foreign material, which were found in 12 patients
(85.7%) each. Organizing thrombus was present in 4 patients (28.6%), valve tissue and/or superﬁcial atrial wall tissue in
9 patients (64.3%), and fragments of myocardium in 2 patients (14.3%). No transient ischemic attacks, strokes, or deaths
occurred peri-procedurally or during a median follow-up interval of 8.4 months.
CONCLUSIONS In this small study of patients undergoing MitraClip treatment with cerebral protection, embolic debris
potentially conducive to cerebrovascular events was found in all patients. Debris was composed most often of acute
thrombus, foreign material likely originating from the hydrophilic device coating, and valve/atrial wall tissue. Further
studies are warranted to assess the impact of cerebral protection on the incidence of cerebrovascular events after
MitraClip therapy. (J Am Coll Cardiol Intv 2016;9:171–9) © 2016 by the American College of Cardiology Foundation.M itral regurgitation (MR) is the secondmost common manifestation of valvularheart disease in adults (1). Since the ﬁrst
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TABLE 1 Baseline Patient Characteristics (N ¼ 14)
Men 7 (50)
Age, yrs 75  7
Body mass index, kg/m2 26  4
Logistic EuroSCORE, % 21 (18–28)
NT-proBNP, pg/ml 5,673 (1,603–12,160)
Left ventricle
End-diastolic diameter, mm 61  9
End-systolic diameter, mm 48  15
Ejection fraction, % 37  16
NYHA functional class
III 8 (57)
IV 6 (43)
ABBR EV I A T I ON S
AND ACRONYMS
ACT = activated clotting time
CPS = cerebral protection
system
IQR = interquartile range
MR = mitral regurgitation
MRI = magnetic resonance
imaging
MVARC = Mitral Valve
Academic Research Consortium
TAVR = transcatheter aortic
valve replacement
TIA = transient ischemic attack
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172consider the MitraClip system to be a treat-
ment option for high-surgical-risk patients
(evidence class IIb) (5,6). Occurrence of a
stroke or a transient ischemic attack (TIA) is
one of the potential complications during
a MitraClip procedure. Incidences of 0.2% to
2.6% have been reported (2,3,7). Blazek et al.
(8) showed that the MitraClip procedure
resulted in new ischemic cerebral lesions on
diffusion-weighted magnetic resonance im-
aging (MRI) in 23 (85.7%) of 27 patients
studied.Arterial hypertension 11/13 (85)
Hyperlipidemia 9 (64)
Diabetes mellitus 5 (36)
SEE PAGE 180Cerebral embolic protection devices for
COPD 5 (36)
Pulmonary hypertension 7 (50)
Atrial ﬁbrillation 8 (57)
Chronic renal insufﬁciency 7 (50)
Coronary artery disease 7 (50)
Previous cardiac surgery 2 (14)
Peripheral arterial disease 3 (21)
Prior stroke 2 (14)
MR etiology
Degenerative 3 (21)
Functional 11 (79)
MR severity
Severe 14 (100)
Values are n (%), mean  SD, or median (interquartile range).
COPD ¼ chronic obstructive pulmonary disease; EuroSCORE ¼ European System
for Cardiac Operative Risk Evaluation; MR ¼ mitral regurgitation; NT-proBNP ¼
N-terminal pro-brain natriuretic peptide; NYHA ¼ New York Heart Association.the prevention of cerebrovascular events have been
introduced for transcatheter aortic valve replacement
(TAVR) procedures (9). Van Mieghem et al. (10) re-
ported on the histopathologic characteristics of debris
captured and retrieved from a ﬁlter-based cerebral
embolic protection device in 30 (75%) of 40 patients
undergoing TAVR. The present study assessed the
feasibility and safety of using a ﬁlter-based cerebral
protection device during MitraClip implantation and
reports on the histopathologic analysis of the debris
captured.
METHODS
PATIENTS. Between July 2014 and March 2015, a total
of 14 surgical high-risk patients underwent a Mitra-
Clip procedure that employed cerebral protection
with the dual-ﬁlter Sentinel system (Claret Medical,
Santa Rosa, California) at 2 German sites (Hamburg
[n ¼ 10] and Aachen [n ¼ 4]). The Hamburg patients
were treated consecutively in 2 series of 6 and 4 pa-
tients; the Aachen patients were selected according to
the patient’s propensity for thromboembolic events
due to echocardiographically detected thrombus
material on pacemaker or deﬁbrillator leads. Four
patients (29%) had an internal cardiac deﬁbrillator
(2 of them as a cardiac resynchronization therapy)
and 1 patient (7%) had a two-chamber pacemaker.
No patient had a porcelain aorta. Pertinent baseline
patient characteristics are given in Table 1.
All patients had severe MR of predominantly
functional origin. Left ventricular function was
impaired, with a mean ejection fraction of 37%, and
all patients presented with reduced physical capacity
(New York Heart Association functional class III or
IV). A history of atrial ﬁbrillation and prior stroke was
present in 8 (57%) and 2 (14%) patients, respectively.
No patient was found to have a thrombus in the left
atrial appendage or the left ventricle. Nine patientswere on oral anticoagulation (phenprocoumon, n ¼ 4;
direct oral anticoagulants, n ¼ 5) without interruption
of the anticoagulation during the MitraClip inter-
vention; 5 patients had dual antiplatelet therapy with
aspirin and clopidogrel. Patients on dual antiplatelet
therapy received a 300-mg loading dose of clopidog-
rel after the MitraClip procedure. Written informed
consent was obtained from all patients.
CEREBRAL PROTECTION DEVICE. The Sentinel
Cerebral Protection System (CPS) comprises 2 bag-
like embolic ﬁlters attached back-to-back to the tip
of a single 6-F compatible catheter, which is
delivered from the right arm via radial or brachial
artery access over a standard 0.014-inch coronary
guidewire (Figure 1). The ﬁlter bags are made of
polyurethane ﬁlm with 140-mm laser-drilled holes,
and each ﬁlter is mounted on a self-expanding
nitinol wire loop. The system is advanced under
ﬂuoroscopic guidance such that the larger proximal
ﬁlter (loop diameter: 9 to 15 mm) is deployed in the
brachiocephalic trunk, and the smaller distal ﬁlter
(loop diameter: 6.5 to 10 mm), which is in an
FIGURE 1 The Cerebral Protection Device Used in This Study
(A) Photograph of the Sentinel Cerebral Protection System (CPS) consisting of 2 ﬁlters for simultaneous protection of both the right side
(proximal ﬁlter) and the left side (distal ﬁlter) of the brain. (B) Schematic of the CPS in place, with the proximal ﬁlter deployed in the bra-
chiocephalic trunk and the distal ﬁlter in the left common carotid artery.
TABLE 2 Procedural Details and Outcome Parameters (N ¼ 14)
Hospitalization, days 7.4  5.0
ICU stay, days 1 (1–2) [n ¼ 6]
Activated clotting time, s 289  48
Contrast agent, ml 12.5 (10–20) [n ¼ 10]
Tamponade 0 (0)
Severe bleeding 0 (0)
Vascular complication 1 (7)
Stroke 0 (0)
TIA 0 (0)
Values are mean  SD, median (interquartile range), or n (%).
ICU ¼ intensive care unit; TIA ¼ transient ischemic attack.
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173articulating sheath inside the proximal ﬁlter, is
placed in the left common carotid artery.
MITRACLIP IMPLANTATION. A standardized anti-
coagulation regimen with heparin was initiated with a
loading dose of 70 IU/kg aiming at an activated clot-
ting time (ACT) between 250 and 300 s. The bolus
of heparin was given after the puncture of all pe-
ripheral vessels. Deployment of the cerebral protec-
tion device was subsequently performed in all
patients via right radial access—that is, before the
transseptal puncture required for MitraClip implan-
tation. Left heart catheterization was not performed
after placement of the CPS.
The procedural details of percutaneous mitral
valve repair using the MitraClip have been described
before (2). All procedures were performed under
general anesthesia in a hybrid operating room. Pro-
cedural success was deﬁned as discharge MR of
maximally moderate severity. Procedural details are
given in Table 2.
After MitraClip implantation, the embolic ﬁlters
were withdrawn into the catheter and removed from
the patient. Outside, the ﬁlters were cut and stored in
10% neutral buffered formalin solution and shipped
to the CVPath Institute (Gaithersburg, Maryland) for
analysis.
HISTOPATHOLOGIC ASSESSMENT OF CAPTURED
DEBRIS. A total of 28 ﬁlters (2 from each patient)
were analyzed. The ﬁlters were photographed (CanonEOS Rebel XSi; Canon U.S.A., Melville, New York),
examined grossly for visible debris, then cut open; all
contents were ﬁltered through a 40-mm nylon cell
strainer (BD Falcon/Corning, Durham, North Car-
olina). The majority of particles detected were
adherent to the ﬁlter, with only a small number of
immersed particles retrieved from the ﬁxative. The
cell-strainer disc was photographed to document
successful debris transfer, and measurements of the
retrieved debris were performed. The specimens
were dehydrated in a graded series of alcohols and
embedded in parafﬁn, and sections of 5 to 6 mm
thickness were cut, with 2 sections mounted on each
glass slide. The sections were stained with hematox-
ylin and eosin and Movat’s pentachrome.
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174The sections were evaluated for the presence of
thrombus, valve and atrial wall tissue, vascular
structures with or without atherosclerotic changes,
myocardial fragments, calciﬁcation, and foreign
material. Thrombus was classiﬁed as acute if it
showed platelets and ﬁbrin with entrapped red blood
cells and acute inﬂammatory cells, or as chronic if the
thrombus showed the presence of spindle-shaped
cells with or without macrophages that lined the
thrombus, inﬁltrated it, or had any organization with
matrix deposition interspersed between the ﬁbrin/
platelet thrombus. Two pathologists reviewed the
slides independently, and the ﬁnal diagnosis was
based on unanimous agreement.
Histopathologic slides were scanned using a digital
slide scanner (Axion Scan.Z1, Carl Zeiss, Thornwood,
New York), and the morphometric analysis was per-
formed using HALO digital image analysis software
(Version 1, Indica Labs, Corrales, New Mexico).
Quantitative measurements were performed on the
20 largest particles identiﬁed in each cross section.
The cumulative area of debris was quantitated in each
cross section using an internal algorithm for auto-
mated particle detection and was expressed as the
cumulative area per case. Minimum and maximum
diameters of individual particles were also
determined.
STATISTICAL ANALYSIS. Continuous variables are
described as mean  SD if normally distributed, or as
median (interquartile range [IQR]) if not. The Mann-
Whitney U test was used to assess between-group
differences in maximum particle diameter, with
p < 0.05 considered statistically signiﬁcant. Categor-
ical variables are described with absolute and relative
frequencies.
RESULTS
PROCEDURAL OUTCOMES. The mean ACT in the 14
procedures was 289  48 s. All procedures were suc-
cessfully completed for both CPS deployment/
retrieval and MitraClip implantation; 6 patients were
discharged with no or trace residual MR, 5 had mild
MR, and 3 patients were discharged with moderate
MR. A single clip was implanted in 7 patients (Hamburg
n ¼ 5, Aachen n ¼ 2); the other 7 patients received 2
clips each. The mean transmitral pressure gradient
after clip implantation was 3.3  1.4 mmHg (range: 1 to
6 mm Hg).
The procedures lasted for a mean of 91  43 min
(range: 40 to 200 min), with a ﬂuoroscopy time of
30 16min (range: 11 to 70min). The total device time—
the time from transseptal puncture to withdrawal ofthe clip delivery system from the left atrium—
amounted to 58  31 min (range: 15 to 130 min).
There were no peri-procedural TIAs or strokes.
A single vascular complication occurred in a patient
in whom the supra-aortic arteries were insufﬁciently
visualized by angiography; the patient experienced
bleeding from a small thyroid artery, which was
treated conservatively by administration of prot-
amine at the end of the procedure. During a median
follow-up period of 8.4 months (IQR: 3.5 to 10.3
months), no patient died or experienced out-of-
hospital TIA or stroke.
HISTOPATHOLOGY. Microscopically, debris was
identiﬁed in all 14 patients. The morphometric anal-
ysis of a total of 515 sections (242 from proximal, 273
from distal ﬁlters) revealed a median cumulative
particle area per patient of 2.46 (IQR: 0.44 to 3.67)
mm2 and a median maximum particle diameter of 295
(IQR: 104 to 509) mm; cumulative areas of debris
captured in proximal and distal ﬁlters were 1.35 (0.30
to 2.09) mm2 and 1.07 (IQR: 0.13 to 2.21) mm2,
respectively, with maximum diameters of 346 (IQR:
211 to 555) mm and 217 (IQR: 63 to 442) mm, respec-
tively (p < 0.0001). The most common tissue types
were acute thrombus (Figure 2A) and small fragments
of nonpolarizable basophilic foreign material
(Figure 3) that was morphologically consistent with
hydrogel, which were found in 12 patients (85.7%)
each. Organizing thrombus (Figure 2B) was present in
4 patients (28.6%), and 2 patients were devoid of any
thrombus. Fibroelastic tissue with proteoglycan
deposition, consistent with either valve tissue and/or
superﬁcial atrial wall tissue (Figure 4), was found in a
total of 9 patients (64.3%). Two patients (14.3%)
showed minute fragments of myocardium. Tissue
particles exhibiting calciﬁcation were not observed in
any of the ﬁlters.
Differentiations of histopathologic ﬁndings ac-
cording to the number of clips implanted and the
study site are given in Tables 3 and 4, respectively. No
difference in the distribution of debris type was
apparent in either analysis. However, the maximum
particle diameters were statistically signiﬁcantly
larger in patients treated with 2 clips (median 402 vs.
134 mm [1 clip], p < 0.0001) and in patients treated
in Aachen (median 411 vs. 262 mm [Hamburg],
p < 0.0001).
The various combinations of types of debris as
found in the individual patients are shown in Figure 5.
The debris was composed of thrombus, valve/atrial
wall tissue, and foreign material in 8 patients (57%),
and of thrombus plus foreign material without any
valve/atrial wall tissue in 3 patients (21%). In 1 patient
FIGURE 2 Type of Thrombus
(A) Acute thrombus with platelet and ﬁbrin (hematoxylin and eosin stained section). (B) Organizing thrombus with matrix deposition of
proteoglycan (yellow arrowheads) (Movat’s pentachrome stained section).
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175each the constituents of debris were thrombus and
myocardial ﬁbers, foreign material and myocardial ﬁ-
bers, and valve/atrial wall tissue only.
The debris was contained in all 14 proximal and all
14 distal ﬁlters. The type of debris captured at the 2
ﬁlter locations is shown in Figure 6. Note the simi-
larity of the distributions, with most ﬁlters at both
locations containing acute thrombus and foreign
material, followed by valve/atrial wall tissue. Two
ﬁlters at either location contained organizing
thrombus, and myocardial ﬁbers were detected only
in 2 distal ﬁlters.FIGURE 3 Foreign Material
(A, B) Basophilic foreign material (yellow arrows) intermingled with acu
(hematoxylin and eosin stained sections).DISCUSSION
MAIN FINDINGS. The main ﬁndings of this small
study of using a dual-ﬁlter CPS during MitraClip
implantation are as follows:
 Using the CPS during a MitraClip procedure is
feasible and safe.
 Debris was found in all patients, with larger parti-
cles identiﬁed in proximal ﬁlters, in patients
treated with 2 clips, and in patients at an increased
risk of thromboembolic events.te ﬁbrin-rich thrombus, rare neutrophils, and thrombocytes
FIGURE 4 Valve Tissue
(A and C) Fibroelastic tissue with proteoglycan deposition corresponding to valve tissue and foreign material (blue arrows). (B) High-power
magniﬁcation of the boxed area in A. (D) High-power magniﬁcation of the boxed area in C. (A, B, C: hematoxylin and eosin stained section; D:
Movat’s pentachrome stained section).
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176 The most prevalent types of debris were acute
thrombus and foreign material consistent with
hydrogel coating.
CLINICAL RELEVANCE. It has been shown that
percutaneous interventional procedures bear the riskTABLE 3 Histopathologic Analysis According to Number of
Clips Implanted
1 Clip
(n ¼ 7)
2 Clips
(n ¼ 7)
Type of debris in ﬁlters
Thrombus 6 (86) 6 (86)
Acute 6 (86) 6 (86)
Organizing 2 (29) 2 (29)
Foreign material 6 (86) 6 (86)
Valve/atrial tissue 4 (57) 5 (71)
Myocardium 2 (29) 0 (0)
Morphometry
Cumulative particle area,
mm2
0.81 (0.36–2.06)
[n ¼ 7]
3.45 (2.80–6.80)
[n ¼ 7]
Maximum particle diameter,
mm
134 (56–336)
[n ¼ 261]
402 (275–589)
[n ¼ 254]
Values are n (%) or median (interquartile range).of new peri-procedural cerebral ischemic events (11).
In a recent consensus document, the Mitral Valve
Academic Research Consortium (MVARC) stated that
stroke and TIA are “clinical endpoints to be collected
in all trials of mitral valve therapies” (12). The inci-
dence of stroke or TIA after a MitraClip procedure of
up to 2.6% (7) justiﬁes any attempt to prevent such
complications.
In this study, the Claret Sentinel device was
used for cerebral protection during MitraClip pro-
cedures. Except for 1 minor vascular complication,
no complications occurred while using this CPS.
The overall procedure duration of 91 min compares
favorably with procedure times reported in the Pi-
lot European Sentinel MitraClip Registry (138 min),
the MitraClip post-approval ACCESS-EU registry
(100 min), and the German transcatheter mitral
valve interventions (TRAMI) registry (103 min)
(3,4,13).
In our series of patients without any peri-
procedural cerebrovascular events, the ﬁlters
captured debris in all patients. A recent diffusion-
weighted MRI study of patients after MitraClip
TABLE 4 Histopathologic Analysis According to Study Site
Hamburg
(n ¼ 10)
Aachen
(n ¼ 4)
Type of debris in ﬁlters
Thrombus 9 (90) 3 (75)
Acute 9 (90) 3 (75)
Organizing 3 (30) 1 (25)
Foreign material 8 (80) 4 (100)
Valve/atrial tissue 8 (80) 1 (25)
Myocardium 1 (10) 1 (25)
Morphometry
Cumulative particle area,
mm2
2.24 (0.44–3.45)
[n ¼ 10]
5.00 (1.13–8.47)
[n ¼ 4]
Maximum particle diameter,
mm
262 (89–442)
[n ¼ 374]
411 (206–647)
[n ¼ 141]
Values are n (%) or median (interquartile range).
FIGURE 6 Type of Captured Debris by Filter Location
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177implantation without cerebral protection revealed an
86% incidence of newly acquired microembolic
cerebral lesions (8), suggesting a strong relationship
between embolic debris captured in ﬁlters during
MitraClip implantation with cerebral protection and
ischemic cerebral lesions detected by MRI after
MitraClip implantation without cerebral protection.FIGURE 5 Distribution of Debris Captured in 14 Patients
Debris was captured by the cerebral protection system’s ﬁlters
in all patients. Pie chart segments represent numbers (and
percentages) of patients with different compositions of debris.
Most often found was a combination of thrombus, valve/atrial
wall tissue, and foreign material (n ¼ 8; light blue segment)
and of thrombus and foreign material without valve/atrial wall
tissue (n ¼ 3; light brown segment). Thrombus plus myocar-
dium, foreign material plus myocardium, and valve/atrial wall
tissue only was found in 1 patient each.
(A) Debris found in the 14 proximal ﬁlters protecting the
brachiocephalic trunk. The majority of ﬁlters (12 [86%] and 9
[64%], respectively) contained acute thrombus and foreign
material; valve/atrial wall tissue was present in 7 ﬁlters
(50%), and organizing thrombus was identiﬁed in 2 ﬁlters
(14%). (B) Debris found in the 14 distal ﬁlters protecting the
left common carotid artery. As in the proximal ﬁlters, the
majority of distal ﬁlters (11 [79%] and 10 [71%], respectively)
contained acute thrombus and foreign material; valve/atrial
wall tissue was present in 5 ﬁlters (36%), and organizing
thrombus and myocardial ﬁbers were identiﬁed in 2 ﬁlters
(14%) each.Although most of the MRI-detected embolic lesions
remained clinically silent, other studies have shown
that clinically silent cerebral lesions were associated
with neurocognitive impairment and the develop-
ment of dementia (14,15).
POTENTIAL ORIGINS OF EMBOLI DURING TRANS-
CATHETER MITRAL VALVE REPAIR. Feld et al. (16)
have shown that the Brockenbrough transseptal
needle generates particles when advanced through
the dilator and transseptal sheath. The particles in
that study were not examined further for the type of
material generated. In our study, foreign particles
found in the ﬁlters consisted of nonpolarizable
basophilic material that was morphologically
consistent with hydrogel. To date, no evidence has
PERSPECTIVES
WHAT IS KNOWN? MitraClip implantation is a
valid therapeutic option to relieve symptoms in
elderly patients with signiﬁcant MR who are
deemed inoperable or at high surgical risk.
Stroke has been observed, if rarely, in associa-
tion with MitraClip therapy, and diffusion-
weighted MRI studies have revealed a high
incidence of new cerebral ischemic lesions after
the intervention.
WHAT IS NEW? The present study of a dual-ﬁlter
cerebral protection system employed during MitraClip
therapy has shown that embolic debris, composed
predominantly of acute thrombus and foreign material
likely originating from the hydrophilic device coating,
was released in all patients.
WHAT IS NEXT? Our ﬁndings warrant further
studies to assess the impact of cerebral protection
on the incidence of cerebrovascular events and
possibly identify patients in whom cerebral protec-
tion should be mandatory during MitraClip
implantation.
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178been found of foreign material arising from the
Sentinel ﬁlter itself and/or its coating. Even after we
manually scraped the surface of ﬁlters, no foreign
material was observed under high-magniﬁcation
microscopy.
Hydrophilic coating is frequently used on medical
devices for interventional procedures to decrease
friction between sheaths or catheters and vessel
walls (17). Mehta et al. (18) identiﬁed hydrophilic
polymer emboli in 9 patients who underwent
various vascular interventions using different
coated devices. Furthermore, multiple ﬁndings of
hydrophilic-coating material in different organs
have been described (19–21). For the MitraClip pro-
cedure several catheters coated with hydrophilic
materials are used, such as the transseptal sheath
for transseptal puncture and the guide catheter for
the MitraClip system. However, it is unknown from
which catheter the majority of foreign material
originated.
The MVARC stated that transcatheter mitral valve
therapies may predispose patients to the formation of
thrombus (12). Acute thrombus could develop at the
transseptal sheath as well as at the guiding catheter
and the clip delivery system due to their thrombo-
genic nature. Maleki et al. (22) reported up to 9%
thrombus formation on regular transseptal sheaths
despite adequate anticoagulation. In our study, anti-
coagulation was adequate (as reﬂected by a mean ACT
of 289 s throughout the procedures). In a cohort of
81 patients who underwent TAVR, thrombotic mate-
rial was found in 74% of patients (23). However,
in that trial the ACT was suboptimal at a mean of
230 s (23).
The origin of the valve and atrial wall tissue
captured in 9 patients (64%) could be generated
from the transseptal puncture and the advancement
of the MitraClip into the left ventricle across
the mitral valve. Furthermore, during grasping of
the mitral leaﬂets some valve tissue might be
embolized.
Calciﬁc debris was not found in any of the ﬁlters
analyzed in our study. This ﬁnding appears to be
consistent with the MRI study by Blazek et al. (8) who
reported no impact of mitral valve calciﬁcation on the
occurrence of embolic lesions.
STUDY LIMITATIONS. The number of patients
enrolled in this study was low. Most patients (11 of 14;
79%) had functional MR. Degenerative MR might be
associated with more valve-related debris. We made
no differentiation with respect to the type of MR. No
brain imaging or assessment of neurocognitive func-
tion before and after the intervention was performed.Both methodological additions to the study protocol
as well as a comparison with a matched cohort of
patients undergoing MitraClip implantation without
cerebral protection would have been desirable.
CONCLUSIONS
In this study of 14 patients undergoing MitraClip
treatment using a CPS, embolic debris potentially
conducive to cerebrovascular events was found in all
patients. The debris was composed most often of
acute thrombus, foreign material likely originating
from the hydrophilic device coating, and valve/atrial
wall tissue. No peri- or post-procedural strokes or
TIAs occurred. Further studies are warranted to
assess the impact of cerebral protection on the inci-
dence of cerebrovascular events after MitraClip
therapy.
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